Last updated on February 2018

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Brief description of study

The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Clinical Study Identifier: NCT02499120

Contact Investigators or Research Sites near you

Start Over

Pfizer Call Center

State Budgetary Healthcare Institution "Oncology Center #2" of the Ministry of
Sochi, Russian Federation
  Connect »